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BACKGROUND & AIM: Aflibercept known as ziv-aflibercept in the United States is a soluble decoy receptor of both
vascular endothelial growth factor (VEGF) receptor-1 and -2 known to inhibit the binding of VEGF and placental
growth factor (PlGF) to VEGF receptor-1 and -2. Here, we analyzed the mechanisms of the antitumor effects of
aflibercept in mouse hepatoma models.METHODS: In in vitro studies, we determined the effects of aflibercept on
human umbilical vein cell (HUVEC) proliferation and bone marrow (BM) cell differentiation to endothelial progenitor
cells (EPCs). In in vivo experiments, aflibercept was injected intraperitoneally in hepatoma cell tumor-bearing mice,
and its inhibitory effects on tumor growth and BM cell migration to tumor tissues were evaluated. RESULTS:
Aflibercept suppressed phosphorylation of VEGF receptor-1 and -2 in HUVEC and dose-dependently inhibited
VEGF-induced HUVEC proliferation. It suppressed the differentiation of BM cells to EPCs and migration of BM cells
to tumor tissues. It also suppressed tumor growth and prolonged survival time of tumor-bearing mice without side
effects. In tumor tissues, aflibercept upregulated the expression of hypoxia inducible factor1-α, VEGF, PlGF,
fibroblast growth factor-2, platelet derived growth factor-BB, and transforming growth factor-α and reduced
microvascular density. It also reduced sinusoidal density in noncancerous liver tissues. CONCLUSIONS: Our
results demonstrated potent antitumor activity for aflibercept in a mouse model of hepatocellular carcinoma.
These effects were mediated through inhibition of neovascularization, caused by inhibition of endothelial cell
proliferation, EPC differentiation, and BM cell migration to tumor tissues.
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Neovascularization is an important process in solid tumor growth [1].
The presence of a highly upregulated angiogenesis process results in
the formation of abnormal and leaky vessel structures, which induce
abnormal blood flow [2,3]. Vascular endothelial growth factor
(VEGF) family members [e.g., VEGFs-A to -E and placental growth
factor (PlGF)-1 and -2] are potent angiogenic factors [4,5]. Recent
studies have suggested that circulating bone marrow (BM)–derived
endothelial progenitor cells (EPC) as well as other BM cells migrate
into tumor tissues to support neovascularization and tumor
development [6–8]. The migration of EPC and other BM cells ismainly regulated by the local release of VEGF, PlGF, and stromal
derived factor-1 in tumor tissues [7,9,10].
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major cause of cancer-related death globally [11]. Although the portal
blood supply to HCC is predominant at the early stage of
hepatocarcinogenesis, HCC ultimately becomes a highly vascular
tumor with the development of neoarteries in parallel with tumor
growth [12,13]. Several reports have stressed the role of VEGF in
such neovascularization process [14,15].
Targeting tumor vasculature as adjunct anticancer therapy was first
advocated by Folkman in 1971 [16]. Since then, numerous
antiangiogenic agents have been used clinically and/or preclinically
to investigate the benefits of such approach in various types of tumors.
Because advanced HCC is a hypervascular tumor, antiangiogenic
therapy might be particularly suitable so as to prevent or halt tumor
growth and even promote tumor regression or dormancy. In 2008,
the therapeutic use of sorafenib, an inhibitor of VEGF receptor-2
(VEGFR)-2, platelet-derived growth factor (PDGF), and Raf/MEK/
ERK signaling, was approved for patients with advanced HCC [17].
However, the therapeutic efficacy of sorafinib proved to be limited.
Aflibercept, a new antiangiogenic agent, is a soluble decoy VEGFR
constructed by fusing the second Ig domain of VEGFR-1 and the
third Ig domain of VEGFR-2 with the constant region (Fc) of human
IgG1 [18]. Because PlGF binds specifically to VEGFR-1 and VEGF
binds to VEGFR-1 and -2, aflibercept shows one-to-one high-affinity
binding to all isoforms of VEGF and PlGF [19,20]. Clinical
randomized phase 3 trial using aflibercept has been performed for
several solid cancers except HCC [21,22]. Then, aflibercept has been
approved by the US Food and Drug Administration for metastatic
colorectal cancer in 2012 [23]. This approval is based on the results of
a randomized, double-blind, placebo-controlled, multicenter trial
enrolling patients with metastatic colorectal cancer, which showed
that a statistically significant improvement of overall survival was
observed in patients in the chemotherapy plus ziv-aflibercept group
compared with the chemotherapy plus placebo group (hazard ratio,
0.82) [24].
In the present study, we investigated the antitumor effects and
antiangiogenic mechanisms of aflibercept in a mouse hepatoma
model. The results demonstrated that aflibercept suppressed tumor
development by inhibiting neovascularization through the suppres-
sion of proliferation of vascular endothelial cells, migration of BM
cells to tumor tissue, and differentiation of EPC.
Materials and Methods
Reagents, Cells, and Animals
Human umbilical vein endothelial cells (HUVECs), mouse
hepatoma cell line (Hepa 1-6), and human hepatoma cell line
(HuH-7) were obtained from CAMBREX Bio Science Walkersville
Inc. (Walkersville, MD). Human hepatoma cell lines (KYN-2 and
HAK1-B) were provided by the Department of Pathology, Kurume
University School of Medicine [25,26]. Male 5-week-old nude mice
(BALB/c nu/nu) and C57BL/6 mice were purchased from Kyudo KK
(Fukuoka, Japan). Male 5-week-old C57BL/6-Tg (act-EGFP)
C14-Y01-FM131Osb mice were generous gifts from Professor
Okabe (Genome Information Research Center, Osaka University,
Osaka, Japan) [27]. All mice were acclimatized to the new laboratory
environment and cared for in separate cages. Furthermore, all animals
received humane care according to the criteria outlined in the “Guide
for the Care and Use of Laboratory Animals” prepared by the
National Academy of Sciences and published by the NationalInstitute of Health. The experimental protocol was approved by the
Laboratory Animal Care and Use Committee of Kurume University.
Proliferation Assay of HUVEC and Hepatoma Cells
HUVEC and hepatoma cells (HuH-7, KYN-2, HAK1-B, Hepa1-6)
were seeded (1 × 103/well) in 96-well plate containing a suitable
medium [EGM-2 supplemented with 5% fetal bovine serum (FBS) for
HUVEC and Dulbecco’s modified Eagle’s medium with 10% FBS for
hepatoma cells]. After 24-hour incubation at 37°C, the media were
replaced with media containing various concentrations of recombinant
VEGF-165 (0, 0.1, 1, 10, 100 pM, 1 nM) (PeproTech, Inc., Rocky
Hill, NJ) or PlGF-2 (0, 0.1, 1, 10, 100 pM, 1 nM) (PeproTech, Inc.)
and 5% FBS for HUVEC cell proliferation assay. To inhibit HUVEC
and hepatoma cell proliferation, the media were replaced with media
containing various concentrations of aflibercept (0, 10, 100 pM, 1, 10,
100 nM) combined with recombinant VEGF-165 (0.2 nM) or PlGF-2
(1.0 nM), and 5%FBS. After 72-hour incubation, cell proliferation was
evaluated by the tetrazolium-based assay (Cell Count Reagent SF;
Nakalai Tesque Inc., Kyoto, Japan). The experiment has been done at
least twice to confirm reproducibility.
Colony-Forming Units (CFU) Assay of EPCs
Bone marrow cells were collected from both femurs of C57BL/6
mice, as reported by Nakamura et al. [28]. EPCs were measured
according to the methods described by Sobrino et al. [29].
Mononuclear cells (5 × 106/well) were seeded on fibronectin-
coated six-well dishes in EndoCult Liquid Medium (StemCell
Technologies, Vancouver, BC, Canada) for 2 days. Then, non-
adherent cells (1 × 106/well) were plated on fibronectin-coated
24-well dishes in a medium containing aflibercept (0, 10 nM).
Colonies formed 3 days later were counted in 10 wells of each group.
To confirm endothelial cell lineage, colonies were incubated with
rabbit anti-mouse CD31 antibody (dilution 1:100; Abcam Japan,
Tokyo, Japan) at 4°C overnight followed by incubation with
fluorescein isothiocyanate (FITC)–conjugated goat anti-rabbit IgG
(dilution 1:100; Dako, Kyoto, Japan). The experiment has been done
at least twice to confirm reproducibility.
Western Blotting of HUVEC and Hepa1-6 Cells
For the investigation of phosphorylation of VEGFR-1 and -2,
HUVEC and Hepa1-6 cells were cultured in serum-free, VEGF-free,
and PlGF-free medium for 6 hours. These cells were preincubated
with aflibercept (0, 3 nM) for 15 minutes. Then recombinant
VEGF-165 or PlGF-2 (0, 1 nM) was added for 5 minutes. Total
protein (10 μg) from each cell lysate was run on 10% sodium dodecyl
sulfate polyacrylamide gel electrophoresis and blotted onto poly-
vinylidene difluoride membranes. The membranes were incubated
overnight with rabbit anti-human phosphorylated–VEGFR-1 anti-
body (Ty1213) (p-VEGFR-1) (dilution 1:500; R&D Systems, Inc.,
Minneapolis, MN), rabbit anti-human p-VEGFR-2 antibody
(Ty1175) (dilution 1:500; Cell Signaling Technology Inc., Danvers,
MA), rabbit anti-human VEGFR-1 antibody (dilution 1:200; Santa
Cruz Biotechnology, Santa Cruz, CA), and rabbit anti-mouse
VEGFR-2 antibody (dilution 1:200; Santa Cruz Biotechnology) at
4°C. After incubation with donkey anti-rabbit HRP-conjugated
antibody (dilution 1:10,000; GE Healthcare Bio-Sciences GK,
Tokyo, Japan) for 1 hour, the immunoreactive bands were stained
using the enhanced chemiluminescence Western blot analysis system
(Amersham Pharmacia Biotech, Piscataway, NJ).
Table 1. Tumor Growth in Three Different Mouse Xenograft Models and Effects of Treatment
with Aflibercept.
Baseline PBS
Group
Baseline Aflibercept
Group
After 3 Weeks
PBS Group
After 3 Weeks
Aflibercept Group
HAK1-B 73.0 ± 21.0 75.2 ± 11.5 213 ± 71.9 15.4 ± 6.6 *
HuH-7 88.2 ± 6.0 92.1 ± 5.6 1,003 ± 573 75.1 ± 23.7 *
Hepa1-6 80.3 ± 14.6 71.7 ± 13.5 1,025 ± 1,013 60.0 ± 42.9 *
Data are mean ± SD of tumor volume (mm3) of six mice per group.
* P b .05, compared with the PBS group at 3 weeks of treatment.
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Figure 1. Inhibitory effects of aflibercept on cell proliferation and phosphorylation of VEGFR-1 and -2.HUVECs were cultured in media
containing aflibercept (0-100 nM); FBS; and (A) VEGF 0.2 nM, (B) PlGF 1.0 nM, or (C) VEGF, PlGF 0 nM. Seventy-two hours after
incubation, cell proliferation was evaluated by a tetrazolium-based assay. (C) HUVECs were cultured in media containing aflibercept and
VEGF. (1) Control, (2) aflibercept, (3) VEGF, (4) VEGF/aflibercept, (5) PlGF, (6) PlGF/aflibercept. (D) BM-derived mononuclear cells were
collected from both femurs of C57BL/6 mice. The expressions of VEGFR-1, VEGFR-2, VEGF, and PlGF were measured by Western
blotting. (F) Images of colony formation assay of EPC in each control and aflibercept-treated group. Statistical comparisons with the
control, *P b .05, by Mann-Whitney U test, **P b .05, by Kruskal-Wallis test. n.s., not significant.
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Model
Nude mice were anesthetized and then injected with 5 × 106
HuH-7, HAK1-B, KYN-2, or Hepa1-6 cells subcutaneously into the
dorsal portions. The tumor-bearing mice of HuH-7, HAK1-B, and
Hepa1-6 cells were randomly divided into phosphate-buffered saline
(PBS)–administered groups and 25.0 mg/kg body weight (BW)
aflibercept-treated groups. On the other hand, the tumor-bearing
mice of KYN-2 cells were randomly divided into four treatment
groups: one PBS-administered group and three aflibercept-treated
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Figure 2. Aflibercept suppresses tumor growth in hepatoma-bearing mice.Data are mean ± SD and expressed relative to the values
immediately after the initiation of treatment (n= 6 per group). (A) HAK1-B cells, (B) HuH-7 cells, (C) Hepa1-6 cells. Initial treatment started
when the average tumor size was 50 to 100 mm3. *P b .05, compared with PBS-treated mice (by Mann-Whitney U test). (D) KYN-2 cells.
Tumor-bearing mice were treated with aflibercept (0-25 mg/kg BW) every 3 days. Gray line represents tumor volume in mice that initiated
aflibercept treatment at day 10. Statistical comparisons with PBS-treated mice, *P b .05, by Mann-Whitney U test, **P b .05, by
Kruskal-Wallis test.
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the average tumor size reached 50 to 100 mm3, and included
intraperitoneal injection of aflibercept or PBS every 3 days. ToTable 2. Changes in Tumor Growth in KYN-2 Xenograft Mice Treated with PBS and Three
Different Doses of Aflibercept.
Baseline After 3-Week Treatment
PBS 72.8 ± 14.0 789 ± 354
6.25 mg/kg BW aflibercept 70.3 ± 18.9 299 ± 318 *
12.5 mg/kg BW aflibercept 79.3 ± 15.8 121 ± 57.2 *
25 mg/kg BW aflibercept 73.2 ± 13.4 77.7 ± 53.5 *
Data are mean ± SD (mm3) of six mice of each group.
* P b .05, compared with the PBS group at 3 weeks.evaluate the therapeutic efficacy of aflibercept in large tumor (i.e.,
equivalent to advanced HCC), treatment with aflibercept was
initiated at 25.0 mg/kg BW in another group of tumor-bearing
mice at day 9. Tumors size was measured by calipers in two
dimensions every 3 days for 3 weeks, and tumor volume was
calculated using the following equation: length × width2 × 0.52. Each
treatment group consisted of six mice. Tumor volume ratio was
calculated by average tumor volume in each measured date/average
tumor volume in the initial treatment date.
Protocols of Growth and Survival Studies of Liver Tumor Model
Nude mice were injected with 2 × 106 KYN-2 cells into the liver.
The mice were randomly divided into PBS-administered group (n =
6) and aflibercept-treated group (25 mg/kg BW, n = 6). Seven days
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Figure 3. Aflibercept inhibits liver tumor growth in nude mice.(A, B) Representative photographs of the liver. Note the large tumor of
KYN-2 cells in the control liver. Tumor growth is markedly suppressed by aflibercept. Yellow circle indicates tumor. (C) Data are mean ±
SD of tumor volume in mm3 (n = 6 per group). *P b .05, compared with PBS-treated mice by Mann-Whitney U test. (D) Kaplan-Meier
estimates of survival of mice treated with aflibercept (25 mg/kg BW) and those treated with PBS. The survival time was counted from the
day of tumor cell transplantation. *P b .05, compared with PBS-treated mice by log-rank test.
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weeks. They were subsequently sacrificed at day 28, and tumor
volume was evaluated. Serum levels of alpha fetoprotein (AFP) were
measured at the time of sacrifice by radioimmunoassay.
For survival studies, KYN-2 cells were inoculated into another
group of 12 nude mice, which was later divided at random into the
control group (PBS-administered, n = 6) and aflibercept-treated
group (25 mg/kg BW, n = 6). Mice were sacrificed when the clinical
signs of weakness, anorexia, and/or N20% weight loss were noted.
Assessment of Microvascular Density, Plasma VEGF and
PlGF, and Peripheral Free Aflibercept Levels of Subcutaneous
Tumor Model
Sections of Hepa1-6 cell tumor tissues and nontumor liver tissues
from mice treated with aflibercept (6.25, 12.5, 25 mg/kg BW) or PBS
were incubated overnight with rabbit anti-mouse CD31 antibody at
4°C. Then, the sections were incubated with FITC-conjugated goatanti-rabbit IgG. CD31-positive blood vessels in tumor tissues and
sinusoids in noncancerous liver tissues were counted in 60 and 25
blindly selected random fields (z-series, 63× oil magnification),
respectively.
Peripheral free aflibercept levels in Hepa1-6 cell tumor-bearing
mice treated with aflibercept (6.25, 12.5, 25 mg/kg BW) were
measured by ELISA [18,19] at the time of sacrifice. Plasma VEGF
and PlGF levels were also measured by ELISA in mice treated with
aflibercept (0, 25 mg/kg BW).
Western Blotting of Tumor Tissues from Subcutaneous Tumor
Model
Hepa1-6 cell tumor tissues were obtained at sacrifice. Total protein
(50 μg) from Hepa 1-6 cell tumor tissues was run on 10% sodium
dodecyl sulfate polyacrylamide gel electrophoresis and blotted onto
polyvinylidene difluoride membrane. The membrane was incubated
overnight with rabbit anti-human p-VEGFR-1 antibody, rabbit
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Figure 4. Effects of aflibercept on phosphorylation of VEGFR-1 and -2, and expression of HIF1-α, VEGF, and PlGF in tumor tissues.(A)
Western blot analysis of pVEGFR-1, pVEGFR-2, VEGFR-1, and VEGFR-2 in Hepa1-6 cell tumor tissue. Lanes 1 to 6, tumor tissues of mice
treated with PBS; lanes 7 to 12, tumor tissues of mice treated with aflibercept (25 mg/kg BW). (B) Western blot analysis of HIF1-α, VEGF,
and PlGF expression in Hepa1-6 cell tumor tissue. Lanes 1 to 6, tumor tissues of mice treated with PBS; lanes 7 to 12, tumor tissues of
mice treated with aflibercept (25 mg/kg BW). The quantified graphs were shown. (C) Quantitative real-time PCR analysis of EGF, FGF-2,
PlGF, HGF, VEGF, Ang-1, Ang-2, PDGF-BB, and TGF-α expression.EGF, epidermal growth factor; HGF, hepatocyte growth factor.
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antibody, rabbit anti-mouse VEGFR-2 antibody, rabbit anti–hypoxia
inducible factor-α (HIF1-α) antibody (Abcam Japan), rabbit
anti-human VEGF antibody (Abcam Japan), rabbit anti-human
PlGF-2 antibody (Abcam Japan), and goat anti-actin antibody (Santa
Cruz Biotechnology) at 4°C. After incubation with donkey
anti-rabbit HRP-conjugated antibody or donkey anti-goat HRP
antibody (dilution 1:2,000; Nacalai Tesque Inc., Kyoto, Japan) for 1
hour, immunoreactive bands were stained by enhanced chemilumi-
nescence Western blot analysis system.
QuantitativeReal-TimePolymeraseChainReaction (PCR)Analysis
Total RNA of Hepa1-6 cell tumor tissues was isolated according to
the Isogen method (Nippon Gene, Tokyo, Japan). One microgram oftotal RNA was reverse transcribed by the TaqMan Reverse
Transcription Reagents kit (Applied Biosystems, Foster City, CA)
using random hexamer primers according to the manufacturer's
instructions. The following TaqMan Gene Expression Assays were
purchased: hgf (Assay ID Mm 01135193_m1), plgf (Assay ID Mm
00435613_m1), fgf-2 (Assay ID Mm 00433287_m1), vegf-a (Assay
ID Mm 01281449_m1), angiopoietin (ang)-1 (Assay ID Mm
00456503_m1), ang-2 (Assay ID Mm 00545822_m1), tgf-α
(Assay ID Mm 000446232_m1), and pdgf-bb (Assay ID Mm
00440677_m1). The levels of PCR products were monitored with a
StepOnePlus Real-Time PCR System (Applied Biosystems). The
baseline and threshold values were adjusted according to the
instructions provided by the manufacturer. The abundance of
transcripts was expressed relative to the constitutive expression level
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Mm00433859_m1).
Migration of BM-Derived Cells to Tumor Tissues
BM-derived mononuclear cells (5 × 106) of C57BL/6-Tg
(act-EGFP) C14-Y01-FM131Osb mice were injected into irradiated
C57BL/6 mice through the tail vein. Six weeks later, 5 × 106
Hepa1-6 cells were implanted subcutaneously into the dorsal
portions. The tumor-bearing mice were randomly divided into
nontreated group, PBS-administered group, and aflibercept-treated
(25.0 mg/kg BW) group. Before the application of any treatment,
tumors of nontreated mice were fixed with 3.7% (vol/vol)
formaldehyde. After 3-week treatment, tumors of PBS- and
aflibercept-treated mice were harvested and fixed with 3.7%
formaldehyde. Sections of tumor tissues were incubated with
FITC-conjugated goat anti–green fluorescent protein (GFP) antibody
(dilution 1: 100; Abcam Japan) for 1 hour at room temperature.
GFP-positive cells in tumor tissues were counted in 10 blindly
selected random fields (z-series, 63× oil magnification).
Measurement of Serum Alanine Aminotransferase (ALT)
Level, BM Functions, and BW of Liver Tumor Model
Leukocyte count, platelet count, hemoglobin (Hb) level, and
serum ALT level were measured at the time of sacrifice. BW was
evaluated at the time of initial administration and at sacrifice.
Statistical Analysis
All data were expressed as mean ± SD. Differences between groups
were examined for statistical significance using the Mann-Whitney Utest, the Kruskal-Wallis rank test, and the log-rank test. A P value less
than .05 denoted the presence of a statistically significant difference.
Results
Effect of Aflibercept for Endothelial Cell and Hepatoma Cell in
Cell Proliferaton Assay
VEGF at ≥100 pM stimulated HUVEC proliferation. However, PlGF
did not induce cell proliferation when used at concentrations up to 1 nM.
Under 0.2-nM VEGF stimulation, aflibercept dose-dependently sup-
pressed VEGF-induced HUVEC proliferation (IC50 = 34 pM) up to 1
nM, then reached a plateau. Aflibercept had no effect on proliferation of
HUVEC incubated with PlGF and control (without VEGF and PlGF)
(Figure 1,A–C). Aflibercept did not suppress the proliferation of hepatoma
cell lines (KYN-2, HuH-7, HAK1-B, and Hepa1-6) (data not shown).
Aflibercept Suppresses the Phosphorylation of VEGFR-1 and -2
on Endothelial Cells
VEGF stimulation upregulated the phosphorylation of VEGFR-1
and -2 on HUVEC and hepatoma cells. On the other hand, PlGF
stimulation upregulated the phosphorylation of VEGFR-1 only.
Aflibercept significantly inhibited the VEGF-stimulated phosphory-
lation of VEGFR-1 and -2 as well as the PlGF-stimulated
phosphorylation of VEGFR-1 but had no effect on the expression
of total VEGFR-1 or -2 in the same cells (Figure 1D).
Aflibercept Inhibits Differentiation of BM-Derived Cells to EPCs
BM-derived mononuclear cells expressed VEGFR-1 and -2. The
same cells also produced VEGF-A and PlGF (Figure 1E). After 5-day
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Figure 5. Aflibercept reduces vascularization in tumor tissue and noncancerous liver tissue.(A, B) Immunohistochemical analysis shows
decreased number of CD 31-positive vessels in tumor tissues of mice treated with aflibercept compared with PBS-treated tumor tissues.
(C, D) Density of CD31-positive vessels in tumor and noncancerous liver tissues. Data are mean ± SD (tumor tissues, 60 fields in 30
sections from each of 6 tumors; noncancerous liver tissue, 25 fields in 18 sections from each of 6 livers). Statistical comparisons with
PBS-treated mice. *P b .05, by Mann-Whitney U test, **P b .05, by Kruskal-Wallis test.
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colonies of EPCs (7.8 ± 2.3 CFU/well). However, aflibercept
significantly inhibited EPC colony formation (3.8 ± 1.1 CFU/well)
(Figure 1F).
Anti-tumor Effect of Aflibercept for Hepatoma Cells in
Subcutaneous Tumor Model
In HAK1-B-, HuH-7-, and Hepa1-6-xenograft models, there were
no significant differences of tumor volume at baseline between
PBS-administrated group and 25 mg/kg BW aflibercept-treated
group. Three weeks later, tumor growth was significantly suppressed
in all mice groups treated with 25 mg/kg BW aflibercept compared
with the respective PBS-administered groups (Table 1). Changes in
tumor volume ratio are depicted in Figure 2, A–C.
In the KYN-2 xenograft model, there were no differences in tumor
volume at baseline between the PBS-administered group and
aflibercept-treated groups. Three weeks later, aflibercept significantly
suppressed tumor growth dose-dependently (Table 2) (Figure 2D). Inanother experiment, treatment commenced when the mean tumor
volume was N350 mm3. The tumor volume at baseline was 360.5 ±
168.2 mm3. After 12 days of treatment, it decreased to 230.0 ± 141.3
mm3 in the 25 mg/kg BW aflibercept-treated group (Figure 2D).
These results indicate that aflibercept significantly suppresses tumor
growth of hepatoma cells in a dose-dependent manner and also
suppresses the growth of advanced tumors.
Aflibercept Suppresses Tumor Growth of Hepatoma Cells and
Serum AFP Levels, and Prolongs Survival of Tumor-BearingMice
Although liver tumors were noted in each mouse (Figure 3, A and
B), in mice inoculated with KYN-2 cells, the tumor volume was
significantly lower in 25 mg/kg BW aflibercept-treated mice than
control mice (PBS, 1317 ± 661; aflibercept, 114 ± 115 mm3)
(Figure 3C).
Serum AFP level was also significantly lower in the
aflibercept-treated group than the control (PBS, 31,237 ± 12,929;
aflibercept, 1422 ± 881 ng/ml).
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median survival time, 68 days) was significantly longer than that of
PBS-administered group (40-61 days; 52 days) (Figure 3D). In this
study, all tumor-bearing mice died of tumor progression.
Aflibercept Suppresses Phosphorylation of VEGFR-1 and -2
and Neovascularization, and Upregulates Expression of HIF1-
α and Angiogenic Growth Factors
Treatment with 25 mg/kg BW aflibercept upregulated plasma
levels of VEGF (PBS, 0.010 ± 0.008; aflibercept, 0.087 ± 0.045 nM)
and PlGF (PBS, 0.0084 ± 0.0064; aflibercept, 0.266 ± 0.010 nM). In
tumor tissues of Hepa1-6 cells, aflibercept significantly suppressed the
phosphorylation of VEGFR-1 and -2 and upregulated the expression
of HIF1-α, VEGF, and PlGF (Figure 4, A and B). Real-time PCR
analysis showed that treatment with 25 mg/kg BW aflibercept
significantly upregulated the expression of fibroblast growth factor-2
(FGF-2), PlGF, VEGF, PDGF-BB, and transforming growth factor
(TGF)–β mRNAs. It also downregulated the expression of Ang-2
mRNA (Figure 4C).
Quantitative analysis of the number of tumor vessels showed that
aflibercept dose-dependently suppressed neovascularization compared
with the control (Figure 5, A–C). In nontumor liver tissues,
aflibercept also reduced sinusoidal density dose-dependently
(Figure 5D).
Peripheral free aflibercept level at sacrifice was 73.0 ± 34.8, 184 ±
139, and 454 ± 273.6 nM in 6.25, 12.5, and 25 mg/kg BW
aflibercept-treated mice, respectively (n = 3).
Aflibercept Inhibits Migration of BM-Derived Mononuclear
Cells to Tumor Tissues
GFP-positive BM-derived cells were identified in tumor
tissues of Hepa1-6 cells (Figure 6A). The mean number of such
cells was 100 ± 12/high-power field at baseline, but aflibercept
significantly suppressed the migration of these cells to tumor tissues
(Figure 6B).Effects of Aflibercept on Leukocyte Count, Hb Levels, Platelet
Count, Serum ALT, and BW in Tumor-Bearing Mice
Treatment with aflibercept did not significantly alter leukocyte
count, platelet count, and Hb levels compared with the control
(Figure 7, A–C). Serum ALT levels and BW were not significantly
different in mice free of tumors and in PBS-administered and
25 mg/kg BW aflibercept-treated tumor-bearing mice (Figure 7, D
and E).
Discussion
The following were the main findings of the present study: 1)
aflibercept significantly suppressed VEGF-induced endothelial cell
proliferation, 2) aflibercept dose-dependently suppressed tumor
growth, 3) the latter effect was mediated through inhibition of
tumor-related neovascularization, and 4) aflibercept did not alter
proliferation of hepatoma cells. These results suggest that the
anticancer effects of aflibercept in our mouse model are mediated
through inhibition of VEGFR signaling-induced tumor
neovascularization.
Neovascularization in solid tumors is induced by several
mechanisms, such as sprouting, intussusceptions, and/or co-option
of local vasculature, and incorporation of BM-derived cells, such as
EPCs [1,8]. The possible mechanisms of vascular growth inhibition
of aflibercept are the following: 1) direct suppression of endothelial
cell proliferation, 2) inhibition of differentiation of BM cells to EPC,
and 3) inhibition of BM cell migration to tumor tissues. VEGFR-1
binds to VEGF with affinity of approximately 10 times that of
VEGFR-2, but its signal-transducing properties are extremely weak
[30]. Deletion of VEGFR-1 in the mouse embryo is lethal because of
vascular overgrowth and disorganization induced by upregulation of
VEGFR-2 signaling [31], whereas loss of the tyrosine kinase domain
of VEGFR-1 alone produces a nearly healthy phenotype with normal
vasculature [32]. In the present study, PlGF did not stimulate
endothelial cell proliferation as reported in the previous study [33].
These findings imply that although VEGF and PlGF phosphorylate
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Figure 7. Lack of side effects of aflibercept on BM function, serum ALT level, and BW.(A) Hemoglobin, (B) leukocyte count, (C) platelet
count, (D) serum ALT, (E) BW.
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thelial cell proliferation [30]. VEGF (0.2 nM)-induced proliferation
of HUVEC was completely inhibited by 1 nM of aflibercept in our in
vitro study. Because aflibercept binds to VEGF at a rate of 1:1 [19],
the concentration of peripheral free aflibercept in aflibercept-treated
mice (6.25 mg/kg BW) was sufficient to induce complete suppression
of endothelial cell proliferation. If this is true, why were the
suppressive effects of aflibercept on tumor neovascularization and
tumor growth dose-dependent? Two possibilities exist. The first is the
difference in concentrations of aflibercept and VEGF in peripheral
blood compared with those in tumor tissues. The other is that
aflibercept does not completely bind to VEGF in the presence of even
sufficient concentrations of aflibercept.Circulating EPC levels are significantly elevated in patients with
advanced HCC compared with patients with early resectable HCC,
patients with liver cirrhosis, and healthy controls [34]. We also
reported previously that EPCs injected into the circulation migrated
to tumor tissues of hepatoma cells and participated in neovascular-
ization [35]. Whyte et al. reported that VEGF-A was strongly induced
by Notch [36]. Coordinated Jagged-1–mediated Notch signaling and
VEGF signaling direct cell differentiation to EPCs in the BM [37]. In
our in vitro study, the addition of aflibercept to media containing
VEGF inhibited the differentiation of BM-derived cells to EPCs.
Aflibercept binds to VEGF, leading to inhibition of VEGF signaling
in BM-derived cells, with subsequent suppression of BM cells
differentiation to EPCs.
Neoplasia Vol. 18, No. 7, 2016 Effect of Aflibercept for Hepatocellular Carcinoma Torimura et al. 423In the present study, BM-derived cells migrated to tumor tissues.
Previous studies showed that the proportions of tumor-associated
macrophages (TAM) and cancer-associated fibroblasts (CAF) were
BM derived [38,39]. CAF, TAM, and other BM-derived cells
participate in tumor neovascularization [8]. CAF and TAM secrete
numerous growth factors, including VEGF, and participate in
neovascularization, EPC recruitment, and tumor cell survival
[40–42]. In the present study, BM-derived cells expressed
VEGFR-1 and -2 and also produced PlGF and VEGF. PlGF
produced in tumor tissues participates in the recruitment of
VEGFR-1+ angiocompetent BM-derived cells, which mostly indi-
rectly promote neovascularization by secreting angiogenic factors
[43]. In comparison, VEGF mainly recruits VEGFR-2+ EPCs from
the BM to sites of tumor neovascularization [5]. In our in vivo study,
serum aflibercept level was high enough to bind to VEGF and PlGF
in the circulation. Thus, it seems that aflibercept binds to VEGF and
PlGF and then inhibits the mobilization and recruitment of
BM-derived cells to tumor tissues.
Our results also showed that aflibercept upregulated HIF1-α
expression in tumor tissues, in addition to the expression of VEGF,
PlGF, FGF-2, PDGF-BB, and TGF-α. Aflibercept-induced suppres-
sion of neovascularization in tumor tissues should result in reduced
local blood supply, leading to a worsened state of tumor tissue
hypoxia. Hypoxic condition triggers upregulation of angiogenic
factors through upregulation of HIF1-α. Upregulated FGF-2,
PDGF-BB, and TGF-α might somewhat induce neovascularization.
Because VEGF is a major mediator of tumor neovascularization [8]
and serum aflibercept concentration was high enough to completely
bind to VEGF and PlGF in tumor-bearing mice, strong inhibition of
VEGF and PlGF signaling seems to suppress tumor neovasculariza-
tion as a whole. Aflibercept downregulated Ang-2 expression. In the
absence of VEGF, Ang-2 is known to promote endothelial cell
apoptosis and vessel regression [44,45]. Based on the inhibitory effect
of aflibercept on VEGF signaling, tumor tissue might downregulate
Ang-2 expression to resist the antiangiogenic effect of aflibercept.
In the orthotopic liver tumor xenograft model, which mirrors the
clinical course of hepatoma more accurately than the subcutaneous
xenograft model, aflibercept did not only induce the suppression of
tumor growth without severe side effects but also improved survival.
In addition, aflibercept also suppressed the growth of large tumors.
These findings suggest that aflibercept is potentially useful for patients
with advanced HCC. However, in this study, we used xenograft
HCC models and thus could not evaluate the effects of liver cirrhosis
on treatment outcome. In fact, the results showed that aflibercept
reduced sinusoidal density in the noncancerous liver tissue. In our
mouse hepatoma model, noncancerous liver tissue was normal. Thus,
aflibercept had no effect on liver function even though sinusoidal
density and sinusoidal blood flow were diminished. Further
investigation using HCC model with liver cirrhosis is required before
any clinical application of aflibercept is possible.
In recent clinical studies on the use of aflibercept in patients with
brain tumors, the most common side effects that resulted in
discontinuation of aflibercept were fatigue, thromboembolic compli-
cations, wound healing complications, and central nervous system
ischemia [46]. Coleman et al. reported that the side effects associated
with aflibercept included grade 1 and 2 hypertension and grade 2
proteinuria in patients with ovarian cancer and fallopian tube cancer.
We did not experience any severe adverse events in tumor-bearing
nude mice [47]. These differences could represent species differences.Aflibercept is not a multisignaling inhibitor, like sorafenib, but only
inhibits VEGFR-1 and -2 signaling. Accordingly, it might have less
severe side effects compared with other antiangiogenic multimolec-
ular targeting agents.
In conclusion, we have demonstrated in the present study that the
antitumor effects of aflibercept in mouse hepatoma model are based
on inhibition of neovascularization through the suppression of
endothelial cell proliferation, BM cell differentiation to EPCs, and
BM-derived cell migration to tumor tissues.
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